CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE MKT: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, today announced that its Chairman and CEO, Paul R. Gudonis, will ring today’s closing bell at the New York Stock Exchange (NYSE) MKT in New York City in commemoration of its initial public offering (IPO) closing on June 9, 2017. Gudonis will be joined by Arthur Jerome “Jay Jay” Johnson, a U.S. veteran from Cleveland, and Jessica Peters, a stroke survivor from Salem, Mass., users of Myomo’s MyoPro myoelectric arm orthosis. The MyoPro is the only lightweight wearable device that helps restore function in the paralyzed or weakened arms and hands of individuals who have suffered a stroke, spinal cord or nerve injury, or other neuromuscular disability.
“We are very pleased to complete our IPO as the first Regulation A+ issuer to trade on the NYSE MKT, providing us with the resources to accomplish our mission of addressing upper limb paralysis with our proprietary life-changing technology,” said Gudonis. “In commemorating our IPO, we acknowledge our broad stakeholder community, including ‘Jay Jay,’ who has successfully regained mobility, and Jessica, who has returned to the workforce and serves as a peer mentor to other young victims of stroke. We also acknowledge the NYSE, in conjunction with the Jumpstart Our Business Startups (JOBS) Act, for paving the way for small growth companies such as ours to raise capital. We look forward to continuing to execute our growth agenda and returning value to our shareholders.”
Gudonis, Johnson and Peters will ring the closing bell at 4:00 PM EDT today, concluding Myomo’s first week of trading on the NYSE MKT. A live stream of the closing bell ceremony can be found at https://livestream.com/nyse.
About Myomo
Myomo, Inc. is a commercial stage medical
robotics Company that offers expanded mobility for those suffering from
neurological disorders and upper limb paralysis. Based on patented
technology developed at MIT and the Company, Myomo develops and markets
the MyoPro® product line of lightweight, non-invasive, powered arm
braces to restore function in the paralyzed or weakened arms and hands
of individuals that have suffered a stroke, spinal cord or nerve injury
such as brachial plexus injury, or other neuromuscular disability such
as amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS). It is
provided through clinical relationships with VA medical centers, leading
rehabilitation hospitals, and Orthotics and Prosthetics (“O&P”)
practices. Several hundred have been successfully used by patients. It
is the only device that, sensing a patient’s own neurological signals
through non-invasive sensors on the arm, can restore their ability to
use their arms and hands so that they can return to work, live
independently and reduce their cost of care. Myomo is headquartered in
Cambridge, Massachusetts, with sales and clinical professionals across
the U.S. For more information, please visit www.myomo.com.
Forward Looking Statements
This press release contains
forward-looking statements regarding the Company's future business
expectations, which are subject to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These forward-looking
statements are only predictions and may differ materially from actual
results due to a variety of factors. Other risks and uncertainties
include, among others, risks related to new products, services, and
technologies, government regulation and taxation, and fraud. More
information about factors that potentially could affect Myomo's
financial results is included in Myomo's filings with the Securities and
Exchange Commission. The Company cautions readers not to place undue
reliance on any such forward-looking statements, which speak only as of
the date made. The Company disclaims any obligation subsequently to
revise any forward-looking statements to reflect events or circumstances
after the date of such statements or to reflect the occurrence of
anticipated or unanticipated events.
DM3\4653643.1
